查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
到 2030 年胃食道逆流症市場預測：按產品、藥物類型、診斷、給藥途徑、配銷通路、最終用戶和地區進行的全球分析
市場調查報告書
商品編碼
1383353

到 2030 年胃食道逆流症市場預測：按產品、藥物類型、診斷、給藥途徑、配銷通路、最終用戶和地區進行的全球分析

Gastroesophageal Reflux Disease Market Forecasts to 2030 - Global Analysis By Product, Drug Type, Diagnosis, Route of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球胃食道逆流症市場規模為 53.7 億美元，預計到 2030 年將達到 69.3 億美元，預測期內年複合成長率為 3.7%。

胃灼熱是一種由胃食道逆流症 (GERD) 引起的灼熱感。此外，逆流是一種向後運動，當胃內容物（包括鹽酸）再次向上移動時，會導致食道下部有灼熱感。

根據美國國家生物技術資訊中心 (NCBI) 2022 年 5 月更新的一篇論文，吸菸被認為是胃酸倒流或酸逆流的病因因素，並且是 50 歲以上人群胃酸倒流的主要危險因素。已經被考慮了。

藥物開發的新方法

製藥業專注於 GERD 的研究和開發，從而開發出安全有效的治療方法。除了開發新配方外，創新還包括個人化醫療策略，根據生活方式和遺傳因素為特定患者量身定做治療方法。透過解決巴雷特食道、食道癌和呼吸系統疾病等 GERD 相關併發症，這些創新提供了更全面的治療和預防方法。

藥物濫用和副作用

質子幫浦抑制劑（PPI）是一種用於治療胃食道逆流的藥物，但由於副作用風險，不宜長期使用。儘管 PPI 很有用，但它們會導致腎功能、骨骼健康和營養吸收不良等問題。此外，患者和醫療保健專業人員很難控制這些副作用並平衡短期症狀緩解與長期健康。

診斷設備技術

早期準確診斷 GERD 的一個關鍵機會是診斷設備的持續改進所帶來的，例如高解析度食道檢測、動態 pH 監測以及共焦雷射內視鏡等先進內視鏡方法。這些設備可以更輕鬆地評估食道損傷的程度，檢測巴雷特食道等併發症，並為選定的患者選擇最佳治療方法。此外，透過獲得更快、更準確的診斷，您可以獲得更有效和個體化的治療，以緩解症狀並預防長期問題。

對藥物治療的耐受性和抗藥性

特別是質子幫浦抑制劑（PPI）不宜長期使用，因為有些患者可能會產生抗藥性或耐受性。隨著時間的推移，這些藥物可能會變得不太有效，需要更高的給藥或其他藥物。此外，尋求更強效藥物或更多治療方法來控制症狀的患者可能會對處方藥物產生抗藥性，使治療決策更加困難並增加醫療費用。

COVID-19 的影響：

胃食道逆流症 (GERD) 和全球醫療保健市場都受到了 COVID-19大流行的嚴重影響。雖然疫情最初對醫療保健服務和供應鏈造成了乾擾，包括胃食道逆流藥物和醫療設備的製造和分銷，但也為病患行為和醫療保健服務帶來了重大變化。此外，關門和其他社交疏遠措施導致胃食道逆流症患者遠端醫療和遠端監控的使用激增，使他們能夠繼續接受治療，同時降低感染病毒的風險。

膠囊細分市場預計將在預測期內成為最大的細分市場

膠囊預計將在胃食道逆流症領域佔據最大的市場佔有率。膠囊因其適應性強、易於製造和對患者友好的特性而被廣泛使用。膠囊提供了一種實用且有效的方式來遞送各種藥物製劑，例如液體、半固體和固體物質。膠囊受到所有年齡層患者的青睞，因為它們劑量精確且易於吞嚥，使其成為處方藥和成藥的熱門選擇。此外，膠囊還可用於廣泛的治療應用，包括特殊藥物、維生素、草藥補充劑和抗生素的配製。

家庭護理產業預計在預測期內年複合成長率最高

在預測期內，年複合成長率最高的將是家庭護理領域。由於高齡化、對舒適環境中個人化照護的渴望以及遠端醫療和醫療技術的進步等多種因素，對家庭護理服務的需求正在顯著增加。此外，居家照護服務涵蓋廣泛的醫療和非醫療支持，這對需要在舒適的家中持續照護、監測和復原的患者俱有吸引力。根據患者的需求，這可能包括物理治療、藥物管理、護理，甚至複雜的醫療程序。

佔比最大的地區：

預計北美地區將佔據最大的市場佔有率。該地區因多種原因而聞名，包括強大的製藥和醫療設備產業、廣泛的醫療基礎設施以及高昂的醫療支出。美國製藥業實力雄厚，尤其是在藥物研發和技術創新方面。北美優勢的另一個因素是其擁有豐富的國際認可的研究中心和醫療設施。此外，北美醫療保健市場不斷變化，越來越重視基於價值的護理、創新治療方法和醫療技術。

複合年複合成長率最高的地區：

市場年複合成長率最高的是亞太地區。多種因素促成了這一強勁成長，包括人口快速成長、都市化加快、醫療保健意識增強以及中國和印度等國家經濟的顯著發展。這些國家正在藥品、醫療技術和醫療保健基礎設施方面進行大量投資。此外，亞太地區已成為著名的臨床試驗和研究中心，吸引了來自世界各地的製藥和醫療設備製造商。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球胃食道逆流症市場：依產品

  • 錠劑
  • 膠囊
  • 暫停
  • 解決方案
  • 其他產品

第6章 全球胃食道逆流症市場：依藥物類型

  • 制酸劑
  • 質子幫浦抑制劑
  • H2受體阻斷劑
  • 促動力劑
  • 多巴胺受體拮抗
  • 末端係緊
  • 史特雷塔
  • 食道
  • 無經口切口
  • 胃底折疊術
  • 其他類型的藥物

第7章 全球胃食道逆流症市場：依診斷

  • 上內視鏡
  • 國外酸（pH）探針測試
  • 食道壓力檢測
  • 其他診斷

第8章 全球胃食道逆流症市場：依給藥途徑

  • 口服
  • 靜脈

第9章 全球胃食道逆流症市場：按配銷通路

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章 全球胃食道逆流症市場：依最終用戶分類

  • 醫院
  • 居家護理
  • 專科診所
  • 其他最終用戶

第11章全球胃食道逆流症市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第12章進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章公司簡介

  • Medtronic Plc
  • Takeda Pharmaceutical Company Limited.
  • Johnson & Johnson Services Inc.
  • GlaxoSmithKline PLC
  • Olympus Corporation
  • TWi Pharmaceuticals, Inc.
  • Ironwood Pharmaceuticals, Inc.
  • SRS Life Sciences
  • Reckitt Benckiser Group PLC
  • Zydus Group
  • AstraZeneca PLC
  • Camber Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Teva Pharmaceuticals Industries Limited.
  • Aurobindo Pharma
  • Sebela Pharmaceuticals
  • Phathom Pharmaceuticals, Inc.
  • SFJ Pharmaceuticals
Product Code: SMRC24203

According to Stratistics MRC, the Global Gastroesophageal Reflux Disease Market is accounted for $5.37 billion in 2023 and is expected to reach $6.93 billion by 2030 growing at a CAGR of 3.7% during the forecast period. Heartburn is a burning sensation that is brought on by a condition called gastroesophageal reflux disease (GERD). Moreover, reflux, a backward movement that produces a burning sensation in the lower part of the esophagus, is what happens when the stomach's hydrochloric acid-containing contents travel upward again.

According to an article updated by the National Center for Biotechnology Information (NCBI) in May 2022, tobacco smoking is considered an etiological factor of reflux esophagitis or acid reflux and it is considered a major risk factor for acid reflux over the age of 50.

Market Dynamics:

Driver:

New approaches to drug development

The pharmaceutical industry's dedication to GERD research and development has resulted in the development of increasingly safe and effective drugs for the condition's management. Additionally, innovations include not only the creation of new drug formulations but also personalized medicine strategies that customize treatments for specific patients based on lifestyle and genetic factors. By addressing GERD-related complications like Barrett's esophagus, esophageal cancer, and respiratory disorders, these innovations offer a more all-encompassing approach to treatment and prevention.

Restraint:

Overuse and adverse reactions to medication

Proton pump inhibitors (PPIs), one type of medication used to treat GERD should not be used for an extended period of time due to the risk of side effects. PPIs are useful, but they raise questions about kidney function, bone health, and nutrient malabsorption. Furthermore, it can be difficult for patients and healthcare professionals to manage these side effects and strike a balance between short-term symptom relief and long-term health.

Opportunity:

Technologies for diagnostic instruments

An important opportunity for the early and precise diagnosis of GERD is provided by continuous improvements in diagnostic tools, such as high-resolution esophageal manometry, ambulatory pH monitoring, and sophisticated endoscopy methods like confocal laser endomicroscopy. These instruments facilitate the evaluation of the degree of esophageal injury, the detection of complications such as Barrett's esophagus, and the choice of the best course of action for selected patients. Moreover, patients can receive more effective and individualized treatments aimed at symptom relief and long-term problem prevention with an earlier and more accurate diagnosis.

Threat:

Tolerance and resistance to medication

Proton pump inhibitors (PPIs) in particular should not be used for extended periods of time, as some patients may develop drug resistance and tolerance. It is possible that these drugs will lose their effectiveness with time and that higher doses or other medications will be necessary. Additionally, patients who seek stronger medications or more therapies to manage their symptoms may become resistant to their prescribed medications, which can make treatment decisions more difficult and raise medical expenses.

COVID-19 Impact:

Gastroesophageal reflux disease (GERD) and the global healthcare market have both been significantly impacted by the COVID-19 pandemic. Significant changes in patient behavior and healthcare delivery were also brought about by the pandemic, even though it first caused disruptions to healthcare services and supply chains, including the manufacture and distribution of GERD medications and medical devices. Furthermore, lockdowns and other social distancing measures led to a spike in the use of telemedicine and remote monitoring for GERD patients, which allowed for continued care while lowering the risk of contracting the virus.

The Capsule segment is expected to be the largest during the forecast period

It is projected that the capsule segment will command the largest market share for gastroesophageal reflux disease. Because of their adaptability, simplicity in production, and patient-friendly qualities, capsules are widely used. They offer a practical and efficient means of delivering a variety of pharmaceutical formulations, such as liquid, semi-solid, or solid substances. Patients of all ages prefer capsules because they provide accurate dosing and ease of swallowing, making them a popular choice for both prescription and over-the-counter medications. Furthermore, capsules can be used for a wide range of therapeutic applications, including the formulation of specialty drugs, vitamins, herbal supplements, and antibiotics.

The Homecare segment is expected to have the highest CAGR during the forecast period

Over the course of the projection period, the homecare segment has shown the highest CAGR. The need for homecare services has increased significantly as a result of a number of factors, such as the aging population, the desire for individualized care in comfortable settings, and developments in telehealth and medical technology. Moreover, homecare services are appealing for patients who need ongoing care, monitoring, or rehabilitation while remaining in their own homes because they cover a wide range of medical and non-medical assistance. Depending on the patient's needs, these services can include physical therapy, medication management, nursing care, and even complex medical procedures.

Region with largest share:

The region of North America is projected to possess the largest market share. The region is well-known for a number of reasons, including a strong pharmaceutical and medical device industry, a large healthcare infrastructure, and high healthcare spending. Particularly in terms of drug development and innovation, the pharmaceutical industry in the United States is substantial. Another factor in North America's dominance is the abundance of internationally recognized research centers and healthcare facilities. Additionally, the North American healthcare market is still changing, with an increasing emphasis on value-based care, innovative therapies, and medical technology.

Region with highest CAGR:

The market's highest CAGR is being experienced by the Asia-Pacific region. Numerous factors, such as the fast-growing population, growing urbanization, increased awareness of healthcare, and significant economic development in nations like China and India, can be credited for this robust growth. These countries are seeing large investments in pharmaceuticals, medical technology, and healthcare infrastructure. Furthermore, the Asia-Pacific area is becoming known as a center for clinical trials and research, drawing pharmaceutical and medical device manufacturers from throughout the world.

Key players in the market

Some of the key players in Gastroesophageal Reflux Disease market include: Medtronic Plc, Takeda Pharmaceutical Company Limited., Johnson & Johnson Services Inc., GlaxoSmithKline PLC, Olympus Corporation, TWi Pharmaceuticals, Inc, Ironwood Pharmaceuticals, Inc., SRS Life Sciences, Reckitt Benckiser Group PLC, Zydus Group, AstraZeneca PLC, Camber Pharmaceuticals, Inc., Pfizer Inc., Teva Pharmaceuticals Industries Limited., Aurobindo Pharma, Sebela Pharmaceuticals, Phathom Pharmaceuticals, Inc. and SFJ Pharmaceuticals.

Key Developments:

In May 2023, Medtronic plc, a global leader in healthcare technology, today announced it has entered into a set of definitive agreements to acquire EOFlow Co. Ltd., manufacturer of the EOPatch® device a tubeless, wearable and fully disposable insulin delivery device. The addition of EOFlow, together with Medtronic's Meal Detection Technology™ algorithm and next-generation continuous glucose monitor, is expected to expand the company's ability to address the needs of more individuals with diabetes, no matter where they are in their treatment journey or preference for how they want their insulin delivered.

In May 2023, Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies.

In January 2023, Takeda has signed an exclusive licence agreement with HUTCHMED (China) and its subsidiary HUTCHMED to develop and market the latter's fruquintinib. Under the deal terms, the company will have an exclusive global licence for the development and commercialisation of fruquintinib for all indications and territories outside of mainland China, Macau, and Hong Kong.

Products Covered:

  • Tablet
  • Capsule
  • Suspension
  • Solution
  • Other Products

Drug Types Covered:

  • Antacids
  • Proton Pump Inhibitors
  • H2 Receptor Blocker
  • Pro Kinetic Agents
  • Dopamine Receptor Antagonist
  • EndoCinch
  • Stretta
  • EsophyX
  • Transoral Incisionless
  • Fundoplication
  • Other Drug Types

Diagnosis Covered:

  • Upper Endoscopy
  • Ambulatory Acid (pH) Probe Test
  • Esophageal Manometry
  • Other Diagnosis

Route of Administrations Covered:

  • Oral
  • Parental

Distribution Channels Covered:

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

End Users Covered:

  • Hospital
  • Homecare
  • Specialty Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Gastroesophageal Reflux Disease Market, By Product

  • 5.1 Introduction
  • 5.2 Tablet
  • 5.3 Capsule
  • 5.4 Suspension
  • 5.5 Solution
  • 5.6 Other Products

6 Global Gastroesophageal Reflux Disease Market, By Drug Type

  • 6.1 Introduction
  • 6.2 Antacids
  • 6.3 Proton Pump Inhibitors
  • 6.4 H2 Receptor Blocker
  • 6.5 Pro Kinetic Agents
  • 6.6 Dopamine Receptor Antagonist
  • 6.7 EndoCinch
  • 6.8 Stretta
  • 6.9 EsophyX
  • 6.10 Transoral Incisionless
  • 6.11 Fundoplication
  • 6.12 Other Drug Types

7 Global Gastroesophageal Reflux Disease Market, By Diagnosis

  • 7.1 Introduction
  • 7.2 Upper Endoscopy
  • 7.3 Ambulatory Acid (pH) Probe Test
  • 7.4 Esophageal Manometry
  • 7.5 Other Diagnosis

8 Global Gastroesophageal Reflux Disease Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Oral
  • 8.3 Parental

9 Global Gastroesophageal Reflux Disease Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacy
  • 9.3 Online Pharmacy
  • 9.4 Retail Pharmacy

10 Global Gastroesophageal Reflux Disease Market, By End User

  • 10.1 Introduction
  • 10.2 Hospital
  • 10.3 Homecare
  • 10.4 Specialty Clinics
  • 10.5 Other End Users

11 Global Gastroesophageal Reflux Disease Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Medtronic Plc
  • 13.2 Takeda Pharmaceutical Company Limited.
  • 13.3 Johnson & Johnson Services Inc.
  • 13.4 GlaxoSmithKline PLC
  • 13.5 Olympus Corporation
  • 13.6 TWi Pharmaceuticals, Inc.
  • 13.7 Ironwood Pharmaceuticals, Inc.
  • 13.8 SRS Life Sciences
  • 13.9 Reckitt Benckiser Group PLC
  • 13.10 Zydus Group
  • 13.11 AstraZeneca PLC
  • 13.12 Camber Pharmaceuticals, Inc.
  • 13.13 Pfizer Inc.
  • 13.14 Teva Pharmaceuticals Industries Limited.
  • 13.15 Aurobindo Pharma
  • 13.16 Sebela Pharmaceuticals
  • 13.17 Phathom Pharmaceuticals, Inc.
  • 13.18 SFJ Pharmaceuticals

List of Tables

  • Table 1 Global Gastroesophageal Reflux Disease Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Gastroesophageal Reflux Disease Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Gastroesophageal Reflux Disease Market Outlook, By Tablet (2021-2030) ($MN)
  • Table 4 Global Gastroesophageal Reflux Disease Market Outlook, By Capsule (2021-2030) ($MN)
  • Table 5 Global Gastroesophageal Reflux Disease Market Outlook, By Suspension (2021-2030) ($MN)
  • Table 6 Global Gastroesophageal Reflux Disease Market Outlook, By Solution (2021-2030) ($MN)
  • Table 7 Global Gastroesophageal Reflux Disease Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 8 Global Gastroesophageal Reflux Disease Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 9 Global Gastroesophageal Reflux Disease Market Outlook, By Antacids (2021-2030) ($MN)
  • Table 10 Global Gastroesophageal Reflux Disease Market Outlook, By Proton Pump Inhibitors (2021-2030) ($MN)
  • Table 11 Global Gastroesophageal Reflux Disease Market Outlook, By H2 Receptor Blocker (2021-2030) ($MN)
  • Table 12 Global Gastroesophageal Reflux Disease Market Outlook, By Pro Kinetic Agents (2021-2030) ($MN)
  • Table 13 Global Gastroesophageal Reflux Disease Market Outlook, By Dopamine Receptor Antagonist (2021-2030) ($MN)
  • Table 14 Global Gastroesophageal Reflux Disease Market Outlook, By EndoCinch (2021-2030) ($MN)
  • Table 15 Global Gastroesophageal Reflux Disease Market Outlook, By Stretta (2021-2030) ($MN)
  • Table 16 Global Gastroesophageal Reflux Disease Market Outlook, By EsophyX (2021-2030) ($MN)
  • Table 17 Global Gastroesophageal Reflux Disease Market Outlook, By Transoral Incisionless (2021-2030) ($MN)
  • Table 18 Global Gastroesophageal Reflux Disease Market Outlook, By Fundoplication (2021-2030) ($MN)
  • Table 19 Global Gastroesophageal Reflux Disease Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 20 Global Gastroesophageal Reflux Disease Market Outlook, By Diagnosis (2021-2030) ($MN)
  • Table 21 Global Gastroesophageal Reflux Disease Market Outlook, By Upper Endoscopy (2021-2030) ($MN)
  • Table 22 Global Gastroesophageal Reflux Disease Market Outlook, By Ambulatory Acid (pH) Probe Test (2021-2030) ($MN)
  • Table 23 Global Gastroesophageal Reflux Disease Market Outlook, By Esophageal Manometry (2021-2030) ($MN)
  • Table 24 Global Gastroesophageal Reflux Disease Market Outlook, By Other Diagnosis (2021-2030) ($MN)
  • Table 25 Global Gastroesophageal Reflux Disease Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 26 Global Gastroesophageal Reflux Disease Market Outlook, By Oral (2021-2030) ($MN)
  • Table 27 Global Gastroesophageal Reflux Disease Market Outlook, By Parental (2021-2030) ($MN)
  • Table 28 Global Gastroesophageal Reflux Disease Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 29 Global Gastroesophageal Reflux Disease Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 30 Global Gastroesophageal Reflux Disease Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 31 Global Gastroesophageal Reflux Disease Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 32 Global Gastroesophageal Reflux Disease Market Outlook, By End User (2021-2030) ($MN)
  • Table 33 Global Gastroesophageal Reflux Disease Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 34 Global Gastroesophageal Reflux Disease Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 35 Global Gastroesophageal Reflux Disease Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 36 Global Gastroesophageal Reflux Disease Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.